127 related articles for article (PubMed ID: 20048712)
1. Epidemiology of treatment failure: a focus on recent trends.
Hull MW; Lima VD; Hogg RS; Harrigan PR; Montaner JS
Curr Opin HIV AIDS; 2009 Nov; 4(6):467-73. PubMed ID: 20048712
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Management of antiretroviral failure and resistance in developing countries.
Hawkins C; Murphy RL
Curr Opin HIV AIDS; 2009 Nov; 4(6):538-44. PubMed ID: 20048723
[TBL] [Abstract][Full Text] [Related]
4. Current status and challenges of antiretroviral research and therapy.
Esté JA; Cihlar T
Antiviral Res; 2010 Jan; 85(1):25-33. PubMed ID: 20018390
[TBL] [Abstract][Full Text] [Related]
5. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
[TBL] [Abstract][Full Text] [Related]
6. Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study.
Bracciale L; Fanti I; Di Giambenedetto S; Colafigli M; Prosperi M; Bacarelli A; Santangelo R; Cattani P; Cauda R; De Luca A
J Clin Virol; 2009 Nov; 46(3):290-4. PubMed ID: 19699675
[TBL] [Abstract][Full Text] [Related]
7. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings.
Lynen L; Van Griensven J; Elliott J
Curr Opin HIV AIDS; 2010 Jan; 5(1):1-5. PubMed ID: 20046141
[TBL] [Abstract][Full Text] [Related]
8. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
9. Effect of antiretroviral resistance on response in treatment-experienced patients.
Kuritzkes DR
AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S5-11. PubMed ID: 19967805
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
[TBL] [Abstract][Full Text] [Related]
11. The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world.
Bennett DE
Curr Opin Infect Dis; 2006 Dec; 19(6):607-14. PubMed ID: 17075338
[TBL] [Abstract][Full Text] [Related]
12. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
Kumarasamy N; Krishnan S
Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven.
Lucas GM
J Antimicrob Chemother; 2005 Apr; 55(4):413-6. PubMed ID: 15722389
[TBL] [Abstract][Full Text] [Related]
15. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
[TBL] [Abstract][Full Text] [Related]
16. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K
Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420
[TBL] [Abstract][Full Text] [Related]
17. Virologic suppression in treatment-experienced patients after virologic rebound or failure of therapy.
Sarmento-Castro R; Vasconcelos C; Aguas MJ; Marques R; Oliveira J
Curr Opin HIV AIDS; 2011 Dec; 6 Suppl 1():S12-20. PubMed ID: 22156775
[TBL] [Abstract][Full Text] [Related]
18. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D
Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188
[TBL] [Abstract][Full Text] [Related]
19. HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries.
Petrella M; Brenner B; Loemba H; Wainberg MA
Drug Resist Updat; 2001 Dec; 4(6):339-46. PubMed ID: 12030782
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
Fischl MA
AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
